Anti-Mouse PD-L1 Monoclonal Antibodies for Flow Cytometry

PA007506.r2b: Recombinant Anti-mouse PD-L1 Monoclonal Antibody (Clone: 10F.9G2.1), Rat IgG2b Kappa

Recombinant Rat IgG2b Monoclonal Antibody. 
Clone: 10F.9G2.1.
Isotype:  Rat IgG2b Kappa.
Source: The anti-mouse PD-L1 monoclonal antibody (clone: 10F.9G2.1) was produced in mammalian cells.
Conjugation: Non-conjugated.
Specificity/Sensitivity: The recombinant 10F.9G2.1 antibody specifically binds to mouse PD-L1 protein.
Applications: Flow cytometry (FC), and Immunohistochemistry - Frozen (IHC-F). 
Form of Antibody: 0.2 uM filtered solution, pH 7.4, containing 0.09% sodium azide.
Purity: >95% by SDS-PAGE under reducing conditions.

PA007506.h1Fs: Recombinant Anti-mouse PD-L1 Monoclonal Antibody (Clone: 10F.9G2.1), Human IgG1 Fc Silent Kappa

Recombinant Human IgG1 Monoclonal Antibody with Fc silent mutation. 
Clone: 10F.9G2.1.
Isotype: Human IgG1 kappa.
Source: The anti-mouse PD-L1 monoclonal antibody (clone: 10F.9G2.1) was produced in mammalian cells.
Conjugation: Non-conjugated.
Specificity/Sensitivity: The recombinant 10F.9G2.1 antibody specifically binds to mouse PD-L1 protein.
Applications: Flow cytometry (FC), and Immunohistochemistry - Frozen (IHC-F). 
Form of Antibody: 0.2 uM filtered solution, pH 7.4, containing 0.09% sodium azide.
Purity: >95% by SDS-PAGE under reducing conditions.

Shipping: The 10F.9G2.1 antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 
12 months from date of receipt, 2 to 8°C as supplied. Do not freeze it.

Background
The rat anti-mouse PD-L1 monoclonal antibody 10F.9G2 (rat IgG2b kappa) reacts with the mouse PD-L1 protein (programmed death ligand-1, B7-H1 or CD274), a member of the B7 family of the Ig superfamily. PD-1 has two ligands, PD-L1 and PD-L2. It has been shown that in mouse models of melanoma, tumor growth can be transiently arrested via treatment with the anti-mouse PD-1 and anti-mouse PD-L1 antibodies which block the interaction between the PD-L1 protein and its receptor PD-1 protein. The 10F.9G2 monoclonal antibody blocks the binding of the mouse PD-L1 protein to the mouse PD-1 protein.
Our recombinant 10F.9G2 antibodies have a part (variable regions) or complete amino acid sequences of the rat anti-mouse PD L1 monoclonal antibody (hybridoma clone name or number: 10F.9G2).

References of anti-mouse PD-L1 antibody (Clone: 10F.9G2):

Antibody-dependent cellular cytotoxicity of anti-programmed death-ligand 1 antibodies for T cells attenuate their antitumor efficacy in a murine tumor model.
Tamemoto, Y. et al. (2025). Int J Pharm. doi: 10.1016/j.ijpharm.2025.125755. PMID: 40412452
In MM48 tumor-bearing mice, MIH6 without ADCC activity inhibited tumor growth by more than 90 %, whereas 10F.9G2 (anti-mouse PD-L1 antibody) with ADCC activity showed slight antitumor effect. The dissociation constant of PD-L1 on MM48 cell surface was approximately 100-fold lower for MIH6 than for 10F.9G2 (anti-mouse PD-L1 mAb). The half-life and amount of intact form of aPD-L1 mAbs (10F.9G2) in tumors were 2.6- and 1.6-fold higher in MIH6 cells than in 10F.9G2 cells, respectively. Only 10F.9G2 (anti-mouse PD-1) antibody reduced the number of CD8 + T cells in MM48 tumor-bearing mice. These results suggest that the difference in efficacy of aPD-L1 mAbs (10F.9G2) could be because aPD-L1 mAbs recognize PD-L1 on T cells, and the number of CD8 + T cells exerting antitumor effect is depleted by 10F.9G2 antibody through ADCC activity.
Tags: 10F.9G2 antibody; anti-mouse PD-L1 antibody

Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity.
Kirchhammer, N. et al. (2023). J Immunother Cancer. 11(5):e006714. doi: 10.1136/jitc-2023-006714. PMID: 37208130
Lack of PD-L1 expression was verified 2 days later by flow cytometry after staining the cells with two clones (MIH5 and 10F.9G2) of PD-L1 antibodies.To ensure the generation of stable PD-L1-KO cells, MC38 cells were stained with a Pe-Cy7-conjugated PD-L1 antibody (clone MIH5) 5 days after electroporation, and PD-L1-negative MC38 cells were FACS-sorted using an FACSMelody Cell Sorter. For intracellular and intranuclear staining, cells were fixed and permeabilized using FoxP3/transcription factor staining buffer set before the incubation with antibodies directed against intracellular antigens. Cell populations were analyzed with BD Fortessa and Cytek Aurora. Tumor-derived cell types were identified using the following combinations of cell markers: Macrophages: CD45 + F4/80 +; Total DCs: CD45 + F4/80 – MHC-II + CD11c +; cDC1: CD45 + F4/80 – MHC-II + CD11c + CCR7 –XCR1 + or CD45 + F4/80 – MHC-II + CD11c + CCR7 – CD103 +; cDC2: CD45 + F4/80 – MHC-II + CD11c + CCR7 – XCR1 – CD11b + or CD45 + F4/80 – MHC + CD11c + CCR7 – XCR1 – SIRPα +; DC3: CD45 + F4/80 – MHC-II + CD11c + CCR7 +; pDC: CD45 + F4/80 – MHC-II + CD11c + SiglecH +; CD8 + T cells: CD45 + F4/80 – CD11c – CD8 +; CD4 + T cells: CD45 + F4/80 – CD4 +; Regulatory T cells (Tregs): CD45 + F4/80 – CD4 + CD25 + FOXP3 +; B cells: CD45 + F4/80 – CD4 – CD8 – CD19 +; Endothelial cells (ECs): CD45 – CD31 +.
Tags: anti-mouse PD-L1 10F.9G2; anti-mouse PD-L1 10F.9G2 for flow cytometry

Tumor-associated neutrophils and macrophages exacerbate antidrug IgG-mediated anaphylactic reaction against an immune checkpoint inhibitor.
Arai, T. et al. (2022). J Immunother Cancer. 10(12):e005657. doi: 10.1136/jitc-2022-005657. PMID: 36543377
Healthy, murine colon 26, CT26, breast 4T1, EMT6, and renal RENCA tumor-bearing mice were treated with an anti-PD-L1 antibody (clone 10F.9G2). Repeated administration of the anti-PD-L1 antibody 10F.9G2 to tumor-bearing mice caused fatal anaphylaxis, depending on the type of tumor model. The levels of ADA in the serum with aPD-1 and aPD-L1 mAbs were determined using bridging ELISA. Anti-PD-1 (RMP1-14) and PD-L1 (10F.9G2 and MIH6) mAbs (2 mg/mL) were immobilized on the surface of microplate wells. Serum was mixed with 10F.9G2 (final concentration of 10F.9G2 was 0.111 mg/mL) in a total volume of 30 µL. After washing the cells with FACS buffer, they were stained with the fluorophore-labeled antibodies listed in online supplemental table S1) for 30 min at 4°C.
Tags: anti-mouse PD-L1 10F.9G2 antibody in cancer research; anti-mouse PD-L1 10F.9G2 in mouse tumor model

89Zr-Labeled Anti-PD-L1 Antibody PET Monitors Gemcitabine Therapy-Induced Modulation of Tumor PD-L1 Expression.
Jung, K-H. et al. (2021). J Nucl Med. 62(5):656–664. doi: 10.2967/jnumed.120.250720. PMID: 32917780
Rat IgG against mouse PD-L1 (10F.9G2) was site-specifically conjugated with deferoxamine-maleimide on sulfohydryl residues. The monoclonal antibody used was a rat IgG2b (10F.9G2 antibody) that specifically binds to the extracellular domain of mouse PD-L1. Cell surface–expressed PD-L1 was assessed by flow cytometry using a phycoerythrin-conjugated antibody against PD-L1 (clone MIH5). Frozen tumor sections underwent overnight incubation at 4°C with a primary antimouse PD-L1 antibody. Overnight incubation was performed at 4°C with rabbit primary antibodies against PD-L1 and phosphorylated forms of AKT (p-AKT) (4058S; 1:1,000), mammalian target of rapamycin (p-mTOR) (2971S; 1:2,000), and phosphatase and tensin homolog (p-PTEN) (9549S; 1:1,000).
Tags: function of anti-mouse PD-L1 10F.9G2; bioactivity of anti-mouse PD-L1 10F.9G2

Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy.
Zhang, J. et al. (2019). J Immunother Cancer. 7(1):223. doi: 10.1186/s40425-019-0693-y. PMID: 31446896
TRAMP/MICB male mice of 26 to 28 week-old were assigned into four cohorts with similar distribution of serum sMIC (Additional file 1: Figure S1) receiving therapy with intraperitoneal (i.p.) injection of sMIC-targeting nonblocking monoclonal antibody B10G5 [ 28] or anti-PD-L1 (clone 10F.9G2, BioXCell) antibody or isotype control IgG (cIgG) respectively at a respective dose of 4.0 mg/kg body weight twice weekly. Combination of the following antibody was used for cell surface or intracellular staining to define populations of NK, CD8, and subsets of CD4 T cells: CD3e (clone 145-2c11), CD8a (clone 53–6.7), CD4 (clone GK1.5), NK1.1 (clone PK136), NKG2D (clone CX5), CD44 (clone eBio4B10), CD11c (clone N418), MHCII (clone M5/114.15.2), CD80 (clone 16-10A1), CD86 (clone PO3) and CD40 (clone 1C10). Multicolored Flow cytometry analyses were performed on an LSR II (BD). Representative histograms from flow cytometry analyses demonstrating the percentage of PD-L1 + tumor cells from TRAMP/MICB mice. Representative histograms from flow cytometry analyses of CD40, CD80 and CD86 expression on DCs from tumor-draining lymph nodes and tumor beds.
Tags: anti-mouse CD274 (PD-L1) [Clone 10F.9G2] - purified; 10F.9G2 anti-mouse PD-L1 antibody

For more references about anti-mouse PD-L1 antibody (Clone: 10F.9G2), please contact our scientific support team with message@sydlabs.com.

Syd Labs provides the following anti-mouse PD-L1 / PD-1 antibodies:
In vivo grade recombinant anti-mouse PD1 antibodies (Clone 29F.1A12.1)
In vivo grade recombinant anti-mouse PD-1 antibodies (Clone RMP1-14.1)
In vivo grade recombinant anti-mouse PD-L1 antibodies (Clone 10F.9G2.1)

Recombinant PD1 and PDL1 Proteins:
Recombinant Human PD-1/PDCD1 Proteins
Biotinylated Recombinant Human PD-1/PDCD1 Proteins
Recombinant Mouse PD-1/PDCD1 Proteins
Biotinylated Recombinant Mouse PD-1/PDCD1 Proteins
Recombinant Cynomolgus PD-1/PDCD1 Proteins
Recombinant Canine PD-1/PDCD1 Proteins
Biotinylated Cynomolgus/Rhesus macaque PD-L1 Protein
Biotinylated Human PD-L1 Protein
Biotinylated Mouse PD-L1 Protein
Cynomolgus PD-L1 Protein
Cynomolgus/Rhesus macaque PD-L1 Protein
Human PD-L1/B7-H1 Protein
Mouse PD-L1/B7-H1 Protein